Open AccessDyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
Author(s) -
Pol Tymon,
Held Claes,
Westerbergh Johan,
Lindbäck Johan,
Alexander John H.,
Alings Marco,
Erol Cetin,
Goto Shinya,
Halvorsen Sigrun,
Huber Kurt,
Hanna Michael,
Lopes Renato D.,
Ruzyllo Witold,
Granger Christopher B.,
Hijazi Ziad
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007444
Subject(s) - medicine , atrial fibrillation , cardiology , apixaban , dyslipidemia , stroke (engine) , apolipoprotein b , apolipoprotein a1 , myocardial infarction , hazard ratio , embolism , edoxaban , cholesterol , warfarin , rivaroxaban , confidence interval , mechanical engineering , engineering , obesity
Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients with atrial fibrillation receiving oral anticoagulation.